Literature DB >> 24166007

Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer.

Terence W Friedlander1, Vy T Ngo, Huan Dong, Gayatri Premasekharan, Vivian Weinberg, Shaun Doty, Qiang Zhao, Elizabeth G Gilbert, Charles J Ryan, Wen-Tien Chen, Pamela L Paris.   

Abstract

The Vitatex cell-adhesion matrix (CAM) platform allows for isolation of invasive circulating tumor cells (iCTCs). Here we sought to determine the utility of prostate-specific membrane antigen (PSMA) as a metastatic castration-resistant prostate cancer (mCRPC) iCTC biomarker, to identify solitary cells and clusters of iCTCs expressing either epithelial, mesenchymal, or stem cell markers, and to explore the feasibility of iCTC epigenomic analysis. CTCs were isolated and enumerated simultaneously using the Vitatex and CellSearch platforms in 23 men with mCRPC. CAM-avid iCTCs were identified as nucleated cells capable of CAM uptake, but without detectable expression of hematopoietic lineage (HL) markers including CD45. iCTCs were enumerated immunocytochemically (ICC) and by flow cytometry. Whole-genome methylation status was determined for iCTCs using the Illumina HumanMethylation27 BeadChip. Thirty-four samples were collected for iCTC analysis. A median of 27 (range 0-800) and 23 (range 2-390) iCTCs/mL were detected by ICC and flow, respectively. In a subset of 20 samples, a median of seven CTCs/mL (range 0-85) were detected by the CellSearch platform compared to 26 by the CAM platform. iCTC clusters were observed in 17% of samples. iCTCs expressing PSMA as well as markers of EMT and stemness were detectable. The iCTC methylation profile highly resembled mCRPC. More CTCs were recovered using the CAM platform than the CellSearch platform, and the CAM platform allowed for the detection of iCTC clusters, iCTCs expressing EMT and stem-cell markers, and characterization of the iCTC methylome. Correlation with clinical data in future studies may yield further insight into the functional significance of these findings.
© 2013 UICC.

Entities:  

Keywords:  circulating tumor cells; epithelial to mesenchymal transition; prostate cancer

Mesh:

Substances:

Year:  2014        PMID: 24166007     DOI: 10.1002/ijc.28561

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  50 in total

Review 1.  Gene expression profiling and DNA methylation analyses of CTCs.

Authors:  Evi S Lianidou
Journal:  Mol Oncol       Date:  2016-02-05       Impact factor: 6.603

Review 2.  Challenges in circulating tumour cell research.

Authors:  Catherine Alix-Panabières; Klaus Pantel
Journal:  Nat Rev Cancer       Date:  2014-07-31       Impact factor: 60.716

3.  Tracking and Functional Characterization of Epithelial-Mesenchymal Transition and Mesenchymal Tumor Cells during Prostate Cancer Metastasis.

Authors:  Marcus Ruscetti; Bill Quach; Eman L Dadashian; David J Mulholland; Hong Wu
Journal:  Cancer Res       Date:  2015-05-06       Impact factor: 12.701

Review 4.  Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies.

Authors:  Emma E van der Toom; Haley D Axelrod; Jean J de la Rosette; Theo M de Reijke; Kenneth J Pienta; Kenneth C Valkenburg
Journal:  Nat Rev Urol       Date:  2019-01       Impact factor: 14.432

Review 5.  Phenotype of circulating tumor cell: face-off between epithelial and mesenchymal masks.

Authors:  Yupeng Hong; Qi Zhang
Journal:  Tumour Biol       Date:  2016-01-13

Review 6.  Circulating tumour cells-monitoring treatment response in prostate cancer.

Authors:  David T Miyamoto; Lecia V Sequist; Richard J Lee
Journal:  Nat Rev Clin Oncol       Date:  2014-05-13       Impact factor: 66.675

Review 7.  Disseminated tumor cells and dormancy in prostate cancer metastasis.

Authors:  Emma E van der Toom; James E Verdone; Kenneth J Pienta
Journal:  Curr Opin Biotechnol       Date:  2016-02-20       Impact factor: 9.740

8.  Evaluation of epithelial-mesenchymal transitioned circulating tumor cells in patients with resectable gastric cancer: Relevance to therapy response.

Authors:  Ting-Ting Li; Hao Liu; Feng-Ping Li; Yan-Feng Hu; Ting-Yu Mou; Tian Lin; Jiang Yu; Lei Zheng; Guo-Xin Li
Journal:  World J Gastroenterol       Date:  2015-12-21       Impact factor: 5.742

9.  Treatment monitoring of patients with epithelial ovarian cancer using invasive circulating tumor cells (iCTCs).

Authors:  Michael L Pearl; Huan Dong; Shaun Tulley; Qiang Zhao; Marc Golightly; Stanley Zucker; Wen-Tien Chen
Journal:  Gynecol Oncol       Date:  2015-03-11       Impact factor: 5.482

Review 10.  Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA.

Authors:  Daniel A Haber; Victor E Velculescu
Journal:  Cancer Discov       Date:  2014-05-06       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.